{
    "id": 5162,
    "fullName": "CDKN2A mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CDKN2A mutant indicates an unspecified mutation in the CDKN2A gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1029,
        "geneSymbol": "CDKN2A",
        "terms": [
            "CDKN2A",
            "ARF",
            "CDK4I",
            "CDKN2",
            "CMM2",
            "INK4",
            "INK4A",
            "MLM",
            "MTS-1",
            "MTS1",
            "P14",
            "P14ARF",
            "P16",
            "P16-INK4A",
            "P16INK4",
            "P16INK4A",
            "P19",
            "P19ARF",
            "TP16"
        ]
    },
    "variant": "mutant",
    "createDate": "04/22/2015",
    "updateDate": "04/24/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18865,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TAPUR), patients with biliary cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.3 weeks and an overall survival of 11.1 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).",
            "molecularProfile": {
                "id": 4974,
                "profileName": "CDKN2A mutant"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 4607,
                "name": "biliary tract cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16508,
                    "pubMedId": null,
                    "title": "Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study",
                    "url": "https://ascopubs.org/doi/10.1200/PO.19.00124"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18863,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TAPUR), patients with pancreatic cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.2 weeks and an overall survival of 12.4 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).",
            "molecularProfile": {
                "id": 4974,
                "profileName": "CDKN2A mutant"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16508,
                    "pubMedId": null,
                    "title": "Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study",
                    "url": "https://ascopubs.org/doi/10.1200/PO.19.00124"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13727,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in CDKN2A results in familial malignant melanoma syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).",
            "molecularProfile": {
                "id": 4974,
                "profileName": "CDKN2A mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17261,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TAPUR), Ibrance (palbociclib) treatment resulted in a disease control rate of 29% (7/28, 1 partial response, 6 stable disease at 16 weeks) in patients with non-small cell lung cancer harboring CDKN2A loss or mutations, with a median progression-free survival of 9.7 weeks and a median overall survival of 20.6 months (J Clin Oncol 37, 2019 (suppl; abstr 9041); NCT02693535).",
            "molecularProfile": {
                "id": 4974,
                "profileName": "CDKN2A mutant"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15295,
                    "pubMedId": null,
                    "title": "Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_252743.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2067,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant human kidney cancer cell line harboring mutations in CDKN2A, SETD2 and VHL demonstrated sensitivity and inhibition of MTORC1 signaling when treated with Sapanisertib (MLN0128) (PMID: 25261369).",
            "molecularProfile": {
                "id": 4976,
                "profileName": "CDKN2A mut SETD2 mut VHL mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2068,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant kidney cancer cell line harboring mutations in CDKN2A and NF2 demonstrated sensitivity and inhibition of MTORC1 signaling when treated with Sapanisertib (MLN0128) (PMID: 25261369).",
            "molecularProfile": {
                "id": 5001,
                "profileName": "CDKN2A mut NF2 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) prevented cell growth and inhibited MTORC1 and MTORC2 signaling in rapamycin-resistant breast cancer cells harboring mutations in BRAF, CDKN2A, KRAS,NF2 and TP53 (PMID: 25261369).",
            "molecularProfile": {
                "id": 5003,
                "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2105,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).",
            "molecularProfile": {
                "id": 5388,
                "profileName": "CDKN2A mut PIK3CA mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6683,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23669,
                "profileName": "CDKN2A mut NRAS act mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6690,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23670,
                "profileName": "BRAF mut CDKN2A mut KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11053,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27904,
                "profileName": "CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H"
            },
            "therapy": {
                "id": 5833,
                "therapyName": "Carboplatin + Imatinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15202,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verzenio (abemaciclib) treatment inhibited Rb1 phosphorylation and tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma harboring CCND1 amplification and CDKN2A mutations (PMID: 30380421).",
            "molecularProfile": {
                "id": 30828,
                "profileName": "CCND1 amp CDKN2A mut"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12822,
                    "pubMedId": 30380421,
                    "title": "Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4974,
            "profileName": "CDKN2A mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4976,
            "profileName": "CDKN2A mut SETD2 mut VHL mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5001,
            "profileName": "CDKN2A mut NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5003,
            "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5388,
            "profileName": "CDKN2A mut PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23648,
            "profileName": "BRAF V600E CDKN2A mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23669,
            "profileName": "CDKN2A mut NRAS act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23670,
            "profileName": "BRAF mut CDKN2A mut KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27904,
            "profileName": "CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30828,
            "profileName": "CCND1 amp CDKN2A mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}